Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
21 hedge funds and large institutions have $5.46M invested in Evoke Pharma in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
8,125% more call options, than puts
Call options by funds: $329K | Put options by funds: $4K
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
11% more funds holding
Funds holding: 19 → 21 (+2)
0.01% less ownership
Funds ownership: 0.1% → 0.09% (-0.01%)
11% less capital invested
Capital invested by funds: $6.17M → $5.46M (-$706K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$85.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$45.2K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$40.5K |
| 4 |
VF
Virtu Financial
New York
|
+$22.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$18.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$549K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$17.5K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$12.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$6.58K |
| 5 |
Citigroup
New York
|
-$1K |
EVOK Hedge Fund Activity: Q3 2021 in Review
21 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2021, worth a combined $5.46M — down 11% from $6.17M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EVOK positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $85.3K. The largest seller was Morgan Stanley, cutting an estimated $549K.
- 21 institutional investors held Evoke Pharma (EVOK) as of Q3 2021, up from 19 in Q2 2021.
- Funds reported $5.46M of Evoke Pharma stock for Q3 2021, down 11% quarter-over-quarter.
- 3 funds opened new Evoke Pharma positions in Q3 2021 and 1 closed out, a net change of +2 holders.
- The largest Evoke Pharma buyer in Q3 2021 was State Street, an estimated $85.3K added.
- The largest Evoke Pharma seller in Q3 2021 was Morgan Stanley, an estimated $549K sold.
Based on aggregated 13F filings for Q3 2021.